Friends for Life® - Orlando 2019 - Sponsors
Platinum Level Sponsors
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com, Lilly Medical, or Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter, and LinkedIn.
In 1923, the founders of Novo Nordisk began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes. Novo Nordisk is proud to be a Bronze Level Sponsor of the Friends for Life conference, supporting the Family Fun Night. Please come see us at the exhibition to find out more about our company and our products. To learn more about Novo Nordisk and our support to the type 1 diabetes community, visit us at www.novonordisk-us.com.
Gold Level Sponsors
Dexcom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.
Silver Level Sponsors
Abbott is a global healthcare leader helping people live more fully at all stages of life. Our FreeStyle Libre portfolio has changed the lives of more than 5.5 million people across more than 60 countries because it is simple, effective and affordable. We’re proud to sponsor the Friends for Life Orlando Conference, raising awareness for diabetes technology to help the 352,000 children and adolescents living with the condition in the U.S. today. Connect with us at https://freestyle.abbott/cwd, on Instagram at @FreeStyleDiabetes, and on Facebook at @FreeStyleUS.
Tandem Diabetes Care creates new possibilities for people living with diabetes, their loved ones, and their healthcare providers through a positively different experience. We manufacture and sell the t:slim X2 insulin pump with Control-IQ technology, but we’re so much more than that. Our company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Since many of our own team members live with type 1 diabetes, or have a loved one impacted by diabetes, the work is personal, and we are committed to the cause. Learn more at tandemdiabetes.com.
Bronze Level Sponsors
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced technology and always-on support when and how it is needed. Medtronic has pioneered first-of-its-kind innovations for over 40 years and is committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. Today we offer the MiniMed™ 780G insulin pump system, the InPen™ smart insulin pen and the i-Port Advance™ injection port, and we continue to innovate further. With a renewed focus on creating products that are easy to use, we hope our future technologies will enable people to focus more on life, and not diabetes. To learn more, visit www.medtronicdiabetes.com and follow us on Facebook, Instagram, TikTok, YouTube and LinkedIn.
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Xeris Pharmaceuticals, Inc.>, the maker of Gvoke HypoPen® (glucagon injection), is dedicated to unlocking the potential of glucagon. We believe that our technology can have a profound impact on the lives of patients and their families. That’s why we are proud to be the first to develop liquid glucagon, but that’s just the beginning. We’re also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue solutions that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com
Friends of CWD
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 82 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
Beta Bionics is a public benefit corporation and certified B corp. committed to commercializing the iLet® bionic pancreas. We’re a people-focused company, here to serve the wider diabetes community. We want to make a difference and aim to improve the lives of people living with diabetes and hope to reduce the data and decision-making overload that PWD and their caregivers often deal with. To learn more about Beta Bionics, our team and our mission visit us at www.betabionics.com and @BetaBionics on social media.
Beyond Type 1 is a global nonprofit dedicated to the diabetes community. We serve the largest digital audience of any diabetes non-profit, and our mission is to help people living with diabetes to stay alive and thrive. Through peer support programs, global campaigns and digital platforms, Beyond Type 1 is uniting the global diabetes community—across all types—helping to change what it means to live with chronic illness.
One of the first sponsors of Children with Diabetes in their very first year, the Diabetes Research Institute and Foundation (DRI/F) are proud to, once again, be a part of this important educational and fun event for those affected by diabetes. The Diabetes Research Institute, a Center of Excellence at the University of Miami Miller School of Medicine, leads the world as the largest and most comprehensive research center dedicated to curing diabetes. The DRI is aggressively working to develop a biological cure by restoring natural insulin production. The Diabetes Research Institute and Foundation were created for one reason – to cure diabetes – which is and will continue to be its singular focus until that goal is reached. For more information, please visit www.DiabetesResearch.org or call 800-321-3437.
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.
With a vision to create a world without limits for people with diabetes, LifeScan is a world leader in blood glucose monitoring – globally more than 20 million people depend on OneTouch brand products to help them manage their diabetes. For over 35 years, LifeScan has had an unwavering commitment to improving the quality of life for people with diabetes by developing products defined by simplicity, accuracy, and trust. For more information, visit www.LifeScan.com and www.OneTouch.com.
MannKind is committed to providing products that allow people living with diabetes to experience life without limits. With Afrezza ® (insulin human) Inhalation Powder and V-Go ® wearable insulin delivery MannKind is focused on being a leader in mealtime control to address this serious unmet need within the diabetes community. Enrollment is currently underway for the INHALE-1 study that is evaluating Afrezza (in combination with basal insulin) for youth aged 4-17 living with type 1 or type 2 diabetes. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Visit us at mannkindcorp.com and learn more about INHALE-1 at clinicaltrials.gov.
Senseonics is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Our CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone. In the U.S., the Eversense System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider.
T1D Exchange is a nonprofit organization that drives improved outcomes in the treatment of type 1 diabetes (T1D). Through quality improvement and collaboration, we harness data and insights to advance T1D research, identify unmet needs in diabetes care, refine best practices and ultimately improve the quality of life for all people living with T1D. The T1D Exchange Registry is a research study open to adults and children with T1D living in the United States. The Registry aims to show how people with T1D are currently doing and how aspects of T1D care and management change over time. Participants complete a questionnaire once per year and can participate in other optional T1D research studies through their Registry Dashboard.
